The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF), already licensed for the treatment of chronic obstructive pulmonary disease ...
(Corrects paragraph 8 to say propellant offers 99.9% lower global warming potential, not "up to 99.9%", after company clarification) (Reuters) -A panel of the European medicines regulator has ...
AstraZeneca has completed the studies that support the first regulatory filings for the transition of Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol ...
(Alliance News) - AstraZeneca PLC on Monday announced that its medicine Trixeo Aerosphere has been approved by the UK Medicines & Healthcare Products Regulatory Agency with "an innovative, ...
(Alliance News) - AstraZeneca PLC on Friday said its therapy for the treatment of chronic obstructive pulmonary disease in adults has received a positive opinion from the European Medicines Agency.
(MENAFN- EIN Presswire) EINPresswire/ -- The global Respiratory Inhaler Devices Market is projected to reach USD 68.1 billion by 2036, rising from USD 38.0 billion in 2026 at a CAGR of 6.0%, according ...
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results